Upregulation of TIGIT and PD-1 in Colorectal Cancer with Mismatch-repair Deficiency
Authors:
- 13 May 2020
- journal article
- research article
- Published by Taylor & Francis in Immunological Investigations
- Vol. 50 (4) , 338-355
Abstract
Background: The role of T cell Ig and ITIM domain (TIGIT) and programmed cell death-1 (PD-1) in colorectal cancer (CRC) with mismatch repair deficiency is unknown. Methods: This was a study of 60 CRC patients with mismatch repair deficiency and 30 healthy controls between June 2015 and October 2015. Results: The expression of Foxp3, PD-1, and TIGIT was higher in cancer tissues compared with adjacent mucosa (all P < .05). Patients with advanced TNM stage had a significantly higher expression of TIGIT (P = .025) and PD-1 (P = .020) than patients with early-stage CRC. The disease-free survival (DFS) of patients with high TIGIT (HR = 3.96, 95%CI: 1.34–11.69, P = .013) or PD-1 (HR = 214.8, 95%CI: 49.88–925.2, P < .001) expression were better. The overall survival (OS) of the patients with CRC and high expression of PD-1 was worse than those with low expression (HR = 4.01, 95%CI:1.26–12.69, P = .019). Conclusion: TIGIT and PD-1 are upregulated in CRC with mismatch repair deficiency and associated with TNM stage and DFS.Keywords
This publication has 63 references indexed in Scilit:
- Comprehensive molecular characterization of human colon and rectal cancerNature, 2012
- Structure of TIGIT immunoreceptor bound to poliovirus receptor reveals a cell–cell adhesion and signaling mechanism that requires cis-trans receptor clusteringProceedings of the National Academy of Sciences, 2012
- Suppression of tumour-specific CD4 + T cells by regulatory T cells is associated with progression of human colorectal cancerGut, 2011
- Rapid Development of Colorectal Neoplasia in Patients With Lynch SyndromeClinical Gastroenterology and Hepatology, 2011
- Targeting Tim-3 and PD-1 pathways to reverse T cell exhaustion and restore anti-tumor immunityJournal of Experimental Medicine, 2010
- The interaction of TIGIT with PVR and PVRL2 inhibits human NK cell cytotoxicityProceedings of the National Academy of Sciences of the United States of America, 2009
- Tumor antigen–specific CD8 T cells infiltrating the tumor express high levels of PD-1 and are functionally impairedBlood, 2009
- Human T Regulatory Cell Therapy: Take a Billion or So and Call Me in the MorningImmunity, 2009
- LAG-3 regulates CD8+ T cell accumulation and effector function in murine self- and tumor-tolerance systemsJournal of Clinical Investigation, 2007
- The multifaceted mismatch-repair systemNature Reviews Molecular Cell Biology, 2006